Phreesia beats by $0.13, reports revs in-line; lowers FY25 revenue guidance raises adjusted EBITDA guidance
- Reports Q1 (Apr) loss of $0.35 per share, $0.13 better than the FactSet Consensus of ($0.48); revenues rose 20.8% year/year to $101.2 mln vs the $100.94 mln FactSet Consensus.
- Average number of healthcare services clients was 4,065 in the quarter, up 23% year-over-year.
- Co lowers guidance for FY25, sees FY25 revs of $416-$426 mln vs. previous guidance of $424-$434 mln, vs. the $427.81 mln FactSet Consensus. Co raises adjusted EBITDA guidance to $21-$26 mln from prior guidance of $12-$20 mln. PHR's outlook reflects the slight impact of the accelerated wind-down of the clearinghouse client relationship and our greater focus on growing profitably1 through a combination of growth and continued margin improvement.
